Press Releases & Presentations

Press Releases & Presentations

Date Title and Summary Additional Formats
Toggle Summary Accelerate Diagnostics, Inc. Announces Pricing of $150 Million Convertible Notes Offering
TUCSON, Ariz. , March 23, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (“ Accelerate Diagnostics”) (NASDAQ:AXDX) today announced the pricing of $150.0 million aggregate principal amount of 2.50% convertible senior notes due 2023 (the “notes”) in a private placement to qualified Read more
View HTML
Toggle Summary Accelerate Diagnostics Inc. Announces $150 Million Convertible Notes Offering
TUCSON, Ariz. , March 22, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced its intention to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of convertible senior notes due 2023 (the “notes”) in a private placement Read more
View HTML
Toggle Summary Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
TUCSON, Ariz. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017 . The company reported revenue for Q4 of $2.1 million , doubling revenue for the year, and signed agreements for Read more
View HTML
Toggle Summary Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February 15, 2018
TUCSON, Ariz. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. will host a conference call on Thursday, February 15, 2018 to review its fourth quarter and full-year financial results for 2017. President and Chief Executive Officer, Lawrence Mehren , joined by Steve Reichling , Chief Read more
View HTML
Toggle Summary Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
TUCSON, Ariz. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of its latest assay for the Accelerate Pheno™ system targeting severe bacterial pneumonia infections. Read more
View HTML
Toggle Summary Accelerate Diagnostics to Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco
TUCSON, Ariz. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren , President and Chief Executive Officer is scheduled to speak at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco . The presentation will take place Wednesday, Read more
View HTML
Toggle Summary Accelerate Diagnostics Joins Sepsis Alliance in Global #GivingTuesday Movement to Raise Awareness of Sepsis as Medical Emergency
TUCSON, Ariz. , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. has teamed up with Sepsis Alliance for #GivingTuesday, November 28 th , a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate Read more
View HTML
Toggle Summary Accelerate Diagnostics Welcomes Dr. Charles Watts to its Board of Directors
TUCSON, Ariz. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced the election of Charles Watts , M.D. to the company's board of directors. His appointment is effective November 14, 2017 . Dr. Watts has held a number of clinical and administrative leadership positions Read more
View HTML
Toggle Summary Accelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare Conference in New York City
TUCSON, Ariz. , Nov. 15, 2017 (GLOBE NEWSWIRE) -- Lawrence Mehren , president and chief executive officer of Accelerate Diagnostics , is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 , at 10:00 AM Eastern Time . Read more
View HTML
Toggle Summary Accelerate Diagnostics reports Q3 2017 financial results
TUCSON, Ariz. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending September 30, 2017 .  The company further reported signed agreements for 295 instruments year to date; contracts for customer evaluations total 239 Read more
View HTML
:

Day High:
Day Low:  
Volume:    

Copyright West LLC. Minimum 15 minutes delayed.


Want to receive investor-related news and updates?

Join our mailing list

Other updates